Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children

Completed

Conditions studied: Pediatrics, Heart Failure, Congenital Heart Disease, Therapeutics

In brief

The purpose of this study is to identify if circulating platelet cyclic adenosine monophosphate (cAMP) levels can be used as a biomarker of milrinone efficacy in children following cardiac surgery or undergoing heart transplant.

Key facts

Study ID

NCT02728128

Run by

University of Colorado, Denver

People needed

53

Starts

2016-08-01

Expected to finish

2017-08-17

Last updated by the study team

2020-03-04

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged birth to 18 year of age
• Surgical complexity STAT score > 3
• Use of cardiopulmonary bypass for cardiac surgery
• Use of milrinone intra-operatively and post-operatively

You may not qualify if…

• Patients on milrinone therapy prior to surgery
• Gestational age less than 34 weeks at the time of surgery
• Weight less than 2500 grams at the time of surgery
• Abnormal renal function prior to cardiac surgery. Abnormal renal function is defined as a serum creatinine > 0.3mg/dL above baseline (lowest value in the preceding 3 months prior to surgery) compared to the level obtained immediately prior to cardiac surgery.

Where it is running

• Children's Hospital Colorado — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.